December 8, 2022 by admin-aurigene Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer Nature 2022,434–439
November 9, 2022 by admin-aurigene PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
November 9, 2022 by admin-aurigene Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
November 15, 2022 by admin-aurigene Safety, tolerability, pharmacokinetics and pharmacodynamics of AUR101, An RORγt inhibitor, in normal healthy volunteers
November 15, 2022 by admin-aurigene Discovery and clinical development of the first small molecule checkpoint inhibitor for cancer therapy
November 15, 2022 by admin-aurigene Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin…
November 15, 2022 by admin-aurigene Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin
